Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1996 Mar;34(3):597–602. doi: 10.1128/jcm.34.3.597-602.1996

Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

N Lehn 1, J Stower-Hoffmann 1, T Kott 1, C Strassner 1, H Wagner 1, M Kronke 1, W Schneider-Brachert 1
PMCID: PMC228854  PMID: 8904422

Abstract

During the years 1992 to 1994, an increase in fluoroquinolone-resistant Escherichia coli was observed at the Medical Center of the Technical University in Munich, Germany. Nineteen strains were collected and were thus available for further analysis. Pulsed-field gel electrophoresis showed clonal diversity in all but two strains. The majority of the patients from whom the strains were isolated had been previously treated with fluoroquinolones. Quinolone resistance was associated with mutations of the quinolone resistance-determining region of the gyrA gene in all cases. Direct sequencing of gyrA PCR amplification products revealed a mutation in codon 83 of the gyrA gene. In some instances the Ser-83-->Leu mutation was accompanied by an Asp-87-->Asn or Asp-87-->Gly mutation. Furthermore, the strains exhibited two different genotypes: in almost half of the fluoroquinolone-resistant E. coli strains as well as in the fluoroquinolone-susceptible E. coli reference strains ATCC 25922 and 35218, silent mutations were detected at bases 255, 273, 300, and 333. Although fluoroquinolones solved major problems in antimicrobial chemotherapy, in certain departments of our hospital the number of resistant E. coli isolates has become so high that susceptibility to fluoroquinolones can no longer be taken for granted.

Full Text

The Full Text of this article is available as a PDF (485.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauernfeind A., Abele-Horn M., Emmerling P., Jungwirth R. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother. 1994 Dec;34(6):1074–1076. doi: 10.1093/jac/34.6.1074. [DOI] [PubMed] [Google Scholar]
  2. Blumberg H. M., Rimland D., Carroll D. J., Terry P., Wachsmuth I. K. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991 Jun;163(6):1279–1285. doi: 10.1093/infdis/163.6.1279. [DOI] [PubMed] [Google Scholar]
  3. Cambau E., Sougakoff W., Besson M., Truffot-Pernot C., Grosset J., Jarlier V. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis. 1994 Aug;170(2):479–483. doi: 10.1093/infdis/170.2.479. [DOI] [PubMed] [Google Scholar]
  4. Chamberland S., Malouin F., Rabin H. R., Schollaardt T., Parr T. R., Jr, Bryan L. E. Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. J Antimicrob Chemother. 1990 Jun;25(6):995–1010. doi: 10.1093/jac/25.6.995. [DOI] [PubMed] [Google Scholar]
  5. Chapman J. S., Bertasso A., Georgopapadakou N. H. Fleroxacin resistance in Escherichia coli. Antimicrob Agents Chemother. 1989 Feb;33(2):239–241. doi: 10.1128/aac.33.2.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cometta A., Calandra T., Bille J., Glauser M. P. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med. 1994 Apr 28;330(17):1240–1241. doi: 10.1056/NEJM199404283301717. [DOI] [PubMed] [Google Scholar]
  7. Dupeyron C., Mangeney N., Sedrati L., Campillo B., Fouet P., Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother. 1994 Feb;38(2):340–344. doi: 10.1128/aac.38.2.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fisher L. M., Lawrence J. M., Josty I. C., Hopewell R., Margerrison E. E., Cullen M. E. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance. Am J Med. 1989 Nov 30;87(5A):2S–8S. doi: 10.1016/0002-9343(89)90010-7. [DOI] [PubMed] [Google Scholar]
  9. Heisig P., Schedletzky H., Falkenstein-Paul H. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother. 1993 Apr;37(4):696–701. doi: 10.1128/aac.37.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Heisig P., Tschorny R. Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro. Antimicrob Agents Chemother. 1994 Jun;38(6):1284–1291. doi: 10.1128/aac.38.6.1284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hooper D. C., Wolfson J. S. Mode of action of the new quinolones: new data. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):223–231. doi: 10.1007/BF01966994. [DOI] [PubMed] [Google Scholar]
  12. Horiuchi S., Inagaki Y., Yamamoto N., Okamura N., Imagawa Y., Nakaya R. Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob Agents Chemother. 1993 Nov;37(11):2486–2489. doi: 10.1128/aac.37.11.2486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jones R. N., Hoban D. J. North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group. Diagn Microbiol Infect Dis. 1994 Jan;18(1):49–56. doi: 10.1016/0732-8893(94)90133-3. [DOI] [PubMed] [Google Scholar]
  14. Jonsson M., Walder M., Forsgren A. First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia. Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):851–853. doi: 10.1007/BF01967392. [DOI] [PubMed] [Google Scholar]
  15. Kern W. V., Andriof E., Oethinger M., Kern P., Hacker J., Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994 Apr;38(4):681–687. doi: 10.1128/aac.38.4.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kern W. V., Markus A., Andriof E. Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis. 1994 Feb;13(2):161–165. doi: 10.1007/BF01982191. [DOI] [PubMed] [Google Scholar]
  17. Kresken M., Hafner D., Mittermayer H., Verbist L., Bergogne-Bérézin E., Giamarellou H., Esposito S., van Klingeren B., Kayser F. H., Reeves D. S. Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Infection. 1994;22 (Suppl 2):S90–S98. doi: 10.1007/BF01793572. [DOI] [PubMed] [Google Scholar]
  18. López-Brea M., Alarcón T. Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter. Eur J Clin Microbiol Infect Dis. 1990 May;9(5):345–347. doi: 10.1007/BF01973741. [DOI] [PubMed] [Google Scholar]
  19. McGowan J. E., Jr Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis. 1983 Nov-Dec;5(6):1033–1048. doi: 10.1093/clinids/5.6.1033. [DOI] [PubMed] [Google Scholar]
  20. Michéa-Hamzehpour M., Auckenthaler R., Regamey P., Pechère J. C. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother. 1987 Nov;31(11):1803–1808. doi: 10.1128/aac.31.11.1803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Moniot-Ville N., Guibert J., Moreau N., Acar J. F., Collatz E., Gutmann L. Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrob Agents Chemother. 1991 Mar;35(3):519–523. doi: 10.1128/aac.35.3.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Muder R. R., Brennen C., Goetz A. M., Wagener M. M., Rihs J. D. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother. 1991 Feb;35(2):256–258. doi: 10.1128/aac.35.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Navarro F., Miró E., Izquierdo C., Mirelis B., Prats G. Increased resistance of enteropathogens to fluoroquinolones in Barcelona, Spain. Eur J Clin Microbiol Infect Dis. 1993 Aug;12(8):645–646. doi: 10.1007/BF01973651. [DOI] [PubMed] [Google Scholar]
  24. Piddock L. J., Hall M. C., Walters R. N. Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains. J Antimicrob Chemother. 1991 Aug;28(2):185–198. doi: 10.1093/jac/28.2.185. [DOI] [PubMed] [Google Scholar]
  25. Pérez-Trallero E., Urbieta M., Jimenez D., García-Arenzana J. M., Cilla G. Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis. 1993 May;12(5):349–351. doi: 10.1007/BF01964432. [DOI] [PubMed] [Google Scholar]
  26. Richard P., Delangle M. H., Merrien D., Barillé S., Reynaud A., Minozzi C., Richet H. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis. 1994 Jul;19(1):54–59. doi: 10.1093/clinids/19.1.54. [DOI] [PubMed] [Google Scholar]
  27. Siitonen A. Escherichia coli in fecal flora of healthy adults: serotypes, P and type 1C fimbriae, non-P mannose-resistant adhesins, and hemolytic activity. J Infect Dis. 1992 Nov;166(5):1058–1065. doi: 10.1093/infdis/166.5.1058. [DOI] [PubMed] [Google Scholar]
  28. Takiff H. E., Salazar L., Guerrero C., Philipp W., Huang W. M., Kreiswirth B., Cole S. T., Jacobs W. R., Jr, Telenti A. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother. 1994 Apr;38(4):773–780. doi: 10.1128/aac.38.4.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Thornsberry C. Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infection. 1994;22 (Suppl 2):S80–S89. doi: 10.1007/BF01793571. [DOI] [PubMed] [Google Scholar]
  30. Vila J., Ruiz J., Marco F., Barcelo A., Goñi P., Giralt E., Jimenez de Anta T. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother. 1994 Oct;38(10):2477–2479. doi: 10.1128/aac.38.10.2477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wang Y., Huang W. M., Taylor D. E. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob Agents Chemother. 1993 Mar;37(3):457–463. doi: 10.1128/aac.37.3.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Weber P., Plaisance J. J., Mancy C. Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli. J Antimicrob Chemother. 1994 Jul;34(1):187–188. doi: 10.1093/jac/34.1.187. [DOI] [PubMed] [Google Scholar]
  33. Wiedemann B., Heisig P. Mechanisms of quinolone resistance. Infection. 1994;22 (Suppl 2):S73–S79. doi: 10.1007/BF01793570. [DOI] [PubMed] [Google Scholar]
  34. Yoshida H., Bogaki M., Nakamura M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother. 1990 Jun;34(6):1271–1272. doi: 10.1128/aac.34.6.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yoshida H., Bogaki M., Nakamura M., Yamanaka L. M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother. 1991 Aug;35(8):1647–1650. doi: 10.1128/aac.35.8.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES